MDS and Secondary AML : An Evolutionary Perspective

  • M. William Audeh
Part of the Cancer Treatment and Research book series (CTAR, volume 108)


The way in which medicine explains disease determines, to a great extent, the approach that is taken to treatment and prevention ([Thagard, 1999]). Myelodysplastic Syndrome (MDS) and its frequent sequela, secondary Acute Myeloid Leukemia (AML), have been explained as clonal disorders of hematopoietic stem cells, which arise as the result of exposure to genotoxic agents, particularly cancer therapies such as chemotherapy and radiation ([Lichtman and Brennan, 2001]). Treatment has until recently been guided by viewing MDS as a disorder of differentiation, or an incipient malignancy requiring additional genotoxic agents to suppress. These assumptions regarding etiology and therapy may be inadequate to answer fundamental questions regarding this disease, such as why only certain individuals exposed to the same chemotherapeutic agents develop MDS/secondary AML, why certain individuals evolve from MDS to secondary AML more rapidly than others, and why treatment with additional genotoxic agents has not proven curative.


Acute Myeloid Leukemia Myelodysplastic Syndrome Acute Myelogenous Leukemia Microsatellite Instability Genetic Instability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Behrens, C., Travis, L.B., Wistuba, I.I., Davis, S., Maitra, A., Clarke, E.A., Lynch, C.F., Glimelius, B., Wiklund, T., Tarone, R., & Gazdar, A.F. (2000) Molecular Changes in Second Primary Lung and Breast Cancers after Therapy for Hodgkin’s Disease.Cancer Epidemiology Biomarkers and Prevention 9: 1027–1035.Google Scholar
  2. Bemauer, U., Vieth, B., Ellrich, R., Heinrich-Hirsch, B., Janig, G.R., & Gundert-Remy, U.(2000) CYP 2E1 expression in bone marrow and its intra-and interspecies variability.Archives of Toxicology73: 618–624CrossRefGoogle Scholar
  3. Berwick, M. & Vineis, P. (2000) Markers of DNA Repair and Susceptibility to Cancer in Humans: An Epidemiologic Review.Journal of the National Cancer Institute92: 874–897PubMedCrossRefGoogle Scholar
  4. Burdon, R. H. (1999)Genes and theEnvironment.Philadelphia. Taylor and Francis, Inc. Caporaso, N. & Rothman, N. (1998) Genetic Susceptibility and Cancer Risk, inHuman Variability in Response to Chemical Exposures. Neuman, D. and Kimmel, C., Editors. Boca Raton. CRC PressGoogle Scholar
  5. Cavalli-Sforza,L.L., Menozzi, P., & Piazza, A. (1994)The History and Geography of Human Genes.Princeton. Princeton University Press.Google Scholar
  6. Chaplain, G., Milan, C., Sgro, C., Carli, P.M., & Bonithon-Kopp, C. (2000) Increased Risk of Acute Leukemia After Adjuvant Chemotherapy for Breast Cancer: A Population-Based Study.Journal of Clinical Oncology18: 2836–2842PubMedGoogle Scholar
  7. Chen, H., Sandler, D.P., Taylor, J.A., Shore, D.L., Liu, E., Bloomfield, C.E., & Bell, D.A. (1996) Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect.Lancet347: 295–287PubMedCrossRefGoogle Scholar
  8. Chen, J., Giovannucci, E., Kelsey, K., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Spiegelman, D., Willett, W.C., & Hunter, D.J. (1996) A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer.Cancer Research56: 4862–4864PubMedGoogle Scholar
  9. Childs, B. (1999)Genetic Medicine: A Logic of DiseaseBaltimore. Johns Hopkins University Press.Google Scholar
  10. Choi, S.W. & Mason, J.B. (2000) Folate and carconigenesis • an integrated scheme.Journal of Nutrition130: 129–132PubMedGoogle Scholar
  11. Cooper, D. N. (1999)Human Gene Evolution.Oxford. Bios Scientific PublishersGoogle Scholar
  12. Crump, C., Chen, C., Applebaum, F.R., Kopecky, K.J., Schwartz, S.M., Willman C.L., Slovak, M.L., & Weiss, N.S. (2000) Glutathion S-Transferase Theta 1 gene Deletion and Risk of Acute Myeloid Leukemia.Cancer Epidemiology Biomarkers and Prevention 9: 457–460Google Scholar
  13. Denamur, E.,Lecointre, G., Darlu, P., Tenaillon, O., Acquaviva, C., Sayada, C., Sunjevaric, I., Rothstein, R., Elion, J., Tadderi, F., Radman, M. & Matie, I. (2000). Evolutionary Implications of the Frequent Horizontal Transfer of Mismatch Repair Genes.Cell 103:711–721PubMedCrossRefGoogle Scholar
  14. Dobzhansky, T. (1970)Genetics of the Evolutionary ProcessNew York. Columbia University Press.Google Scholar
  15. Ewald, P. (1994)Evolution of Infectious Disease.New York. Oxford University Press.Google Scholar
  16. Felix, C.A., Walker, A.H., Lange, B.T., Williams, T.M., Winick, N.J., Cheung, N.K., Lovett, B.D., Nowell, P.C., Blair, I.A., & Rebbeck, T.R. (1998) Association of CYP3A4 genotype with treatment-related leukemia.Proceedings National Academy of Sciences 95:13176–13181CrossRefGoogle Scholar
  17. Frame, L.T., Ambrosone, C.B., Kadlubar, F.F., & Lang, N.P. (1998) Host-Environment Interactions That Affect Variability in Human Cancer Susceptibility, inHuman Variability in Response to Chemical Exposures. Neuman, D. and Kimmel, C., Editors. Boca Raton. CRC Press.Google Scholar
  18. Greaves, M. (2000)Cancer: The Evolutionary Legacy.New York. Oxford University PressGoogle Scholar
  19. Hanahan, D. & Weinberg, R. (2000) The Hallmarks of Cancer.Cell 100:57–70PubMedCrossRefGoogle Scholar
  20. Hastings, P.J., Bull, H.J., Klump, J.R., & Rosenberg, S.M. (2000) Adaptive Amplification: An Inducible Chromosomal Instability Mechanism.Cell 103:723–731PubMedCrossRefGoogle Scholar
  21. Hirst, W.J., Czepulkowski, B. & Mufti, G.J. (1993) Consistent interstitial chromosomal deletions in myeloid malignancies and their correltaion with fragile sites.Cancer Genetics and Cytogenetics. 65:51–57PubMedCrossRefGoogle Scholar
  22. Hoffman, A.A. & Parsons, P.A. (1993)Evolutionary Genetics and Environmental StressNew York. Oxford University Press.Google Scholar
  23. Kurotaki, H., Tsushima, Y., Nagai, K., & Yagihashi, S. (1999) Apoptosis, bel-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.Acta Haematologica 102, 115–123.CrossRefGoogle Scholar
  24. Lazar, M. A. (2000) Gene Regulation: One man’s food.Nature 407:852–853PubMedCrossRefGoogle Scholar
  25. Lensch, M.W., Rathbun, R.K., Olson, S.B., Jones, G.R., & Bagby, G.C. (1999) Selective Pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemiaLeukemia 13:1784–1789PubMedCrossRefGoogle Scholar
  26. Lichtman, M. & Brennan, J. K. (2001) Chapter 92: Myelodysplastic Disorders, inWilliams Hematology 6` h Edition.New York. McGraw-HillGoogle Scholar
  27. Maeck, L., Haase, D., Schoch, C., Hiddeman, W., & Alves, F. (2000) Genetic instability in myelodysplastic syndrome: detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations.British Journal of Hematology 109:842–846Google Scholar
  28. Mori, N., Morosetti, R., Hoflehner, E., Lubbert, M., Mizoguchi, H., & Koeffler, H. (2000) Allelic loss in the progression of myelodysplastic syndrome.Cancer Research 60:3039–3042PubMedGoogle Scholar
  29. Neel, J.V. (1999) When Some Fine Old Genes Meet a “New” Environment, in Evolutionary Aspects of Nutrition and Health, Simopoulos, A.P., Editor. Basel. KargerGoogle Scholar
  30. Nesse, R. & Williams, G. (1994)Why We Get Sick: The New Science of Darwinian MedicineNew York. Random House.Google Scholar
  31. Ponten, J. (1998)Cancer Surveys: Precancer: Biology Importance and Possible Prevention. New York. Cold Spring Harbor Laboratory Press.Google Scholar
  32. Stearns, S. C. (1999)Evolution in Health and Disease.New York. Oxford University Press Sullivan, N. F. & Willis, A. E. (1994) Chapter 8: Acquisition of Premalignant Lesions: Myelodysplastic Syndrome, inThe Molecular Mechanisms of Cancer Predisposition. Google Scholar
  33. Thagard, P. (1999)How Scientists Explain Disease.Princeton. Princeton University PressGoogle Scholar
  34. Weatherall, D.J. (1996) The genetics of common diseases: the implications of population variability, inVariation in the Human Genome.(Ciba Foundation Symposium 197) Chichester. WileyGoogle Scholar
  35. Weiss, K. W. (1993)Genetic Variation and Human Disease: Principles and Evolutionary Approaches.New York. Cambridge University PressGoogle Scholar
  36. Willman, C. (2000) Biologic and Genetic Features of the Myelodysplastic Syndrome.Hematology 2000p100–1Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • M. William Audeh
    • 1
    • 2
  1. 1.University of CaliforniaLos Angeles
  2. 2.Division of Hematology/OncologyCedars-Sinai Medical CenterLos Angeles

Personalised recommendations